DE3715281A1 - Substance with antiviral activity - Google Patents
Substance with antiviral activityInfo
- Publication number
- DE3715281A1 DE3715281A1 DE19873715281 DE3715281A DE3715281A1 DE 3715281 A1 DE3715281 A1 DE 3715281A1 DE 19873715281 DE19873715281 DE 19873715281 DE 3715281 A DE3715281 A DE 3715281A DE 3715281 A1 DE3715281 A1 DE 3715281A1
- Authority
- DE
- Germany
- Prior art keywords
- benzamide
- hepatitis
- infection
- substance
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000126 substance Substances 0.000 title abstract description 4
- 230000000840 anti-viral effect Effects 0.000 title description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 13
- 208000015181 infectious disease Diseases 0.000 abstract description 12
- 208000006454 hepatitis Diseases 0.000 abstract description 10
- 231100000283 hepatitis Toxicity 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Bekanntlich ist die Hepatitis eine hepatozelluläre entzündliche Erkrankung der Leber. Neben chemischen Noxen, wie Alkohol, Arzneimittel und Gifte lösen besonders Viren eine Hepatitis aus. Am schlimmsten sind die Viren als Auslöser. So unterscheiden wir eine Virus-A-Hepatitis, eine Virus-B-Hepatitis und eine Non-A-Non-B-Hepatitis. Das klinische Erscheinungsbild der Virushepatiden ist ähnlich, nur verlaufen die Hepatitis B und Non-A-Non-B schwerer und langwieriger. Die Viren, welche Hepatitis hervorrufen, kurz Hepatitis-Viren bezeichnet, gehören zur Coronavirusgruppe. Die Erforschung dieser Gruppe von Viren ist mit Tierversuchen verbunden. Es wird mit dem MHV3-Hepatitis-Virus der Maus gearbeitet. Dieses erzeugt eine seuchenhaft verlaufende Hepatitis. Therapeutisch werden antivirale Substanzen verschiedenartiger Struktur mit wenig Erfolg eingesetzt.Hepatitis is known to be a hepatocellular inflammatory Liver disease. In addition to chemical pollutants, such as alcohol, pharmaceuticals and poisons particularly cause viruses to cause hepatitis. The worst are the viruses as triggers. So differentiate we have virus A hepatitis, virus B hepatitis and one Non-A-Non-B hepatitis. The clinical appearance of viral hepatids is similar, only the hepatitis B and Non-A-Non-B heavy and lengthy. The viruses, which Cause hepatitis, abbreviated hepatitis viruses, belong to the corona virus group. Researching this group of viruses is associated with animal testing. It is made with the MHV3 hepatitis virus the mouse worked. This creates an epidemic Hepatitis. Antiviral substances become therapeutic different structure used with little success.
Es wurde nun die überraschende Beobachtung gemacht, daß das einfache Benzamid der nachfolgenden StrukturThe surprising observation has now been made that the simple benzamide of the structure below
eine MHV3-Infektion der Maus zu heilen vermag. Diese Wirkung ist überraschend und in keiner Weise zu erwarten gewesen. Sie ist erfinderisch wertvoll. Die Wirkung läuft vermutlich über eine Beeinflussung des Adenoribosylierungs-Stoffwechsels.an MHV3 infection of the mouse is able to cure. This effect is surprising and in no way expected. they is inventive and valuable. The effect is likely to overflow an influence on the adenoribosylation metabolism.
Benzamid soll in Form von Kapseln, Tabletten und Lösungen hergestellt werden und nach allgemein bekannten Methoden der Galenik Verwendung finden als Arzneimittel in der Human- und Veterinär medizin. Benzamide is said to be produced in the form of capsules, tablets and solutions and according to generally known methods of galenics Find use as medicines in human and veterinary medicine.
1,5 g/kg Benzamid zeigte keinen Effekt. Bei 2,0 g/kg Benzamid starben 75% der Versuchstiere.1.5 g / kg benzamide showed no effect. At 2.0 g / kg Benzamide died 75% of the experimental animals.
Eine dreimalige Gabe von jeweils 25 mg/kg Benzamid bewirkt eine Heilung von 60% der Tiere (siehe Abb. 1). Keines der Tiere ist danach mehr verstorben.A dose of 25 mg / kg benzamide three times causes 60% of the animals to heal (see Fig. 1). None of the animals died afterwards.
Aus den Tabellen 1 und 2 ist zu entnehmen, daß der Anstieg der beiden Serum-Enzyme GOT und GPT durch Benzamid erheblich reduziert wird.Tables 1 and 2 show that the increase of the two serum enzymes GOT and GPT significantly due to benzamide is reduced.
Auch im histologischen Bild zeigt sich, daß Benzamid
die Leber gegen den der Viren schützt. Auf Wunsch
reichen wird die entsprechenden Bilder gerne nach.
Infektion:MHV-3-Virus; Infektion zum Zeitpunkt 0
Benzamid-Applikation:25 mg/kg jeweils
1 Stunde nach Infektion
24 Stunden nach Infektion
48 Stunden nach Infektion
Anzahl der Tiere:jeweils 5 pro GruppeThe histological picture also shows that benzamide protects the liver against that of the viruses. Upon request, the corresponding pictures will be happy to provide.
Infection: MHV-3 virus; Infection at time 0 benzamide application: 25 mg / kg each
1 hour after infection
24 hours after infection
48 hours after infection Number of animals: 5 per group
Infektion:MHV-3-Virus; Infektion zum Zeitpunkt 0
Benzamid-Applikation:25 mg/kg jeweils
1 Stunde nach Infektion
24 Stunden nach Infektion
48 Stunden nach Infektion
Anzahl der Tiere:jeweils 5 pro Gruppe Infection: MHV-3 virus; Infection at time 0 benzamide application: 25 mg / kg each
1 hour after infection
24 hours after infection
48 hours after infection Number of animals: 5 per group
Claims (1)
dadurch gekennzeichnet
- 1. daß Benzamid der Formel verwendet wird.
- 2. Verwendung in der Human- und Veterinärmedizin als Arzneimittel.
- 3. Verwendung in pharmazeutischer Zubereitung nach herkömmlicher Art.
characterized
- 1. that benzamide of the formula is used.
- 2. Use in human and veterinary medicine as a pharmaceutical.
- 3. Use in pharmaceutical preparation in the conventional manner.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873715281 DE3715281A1 (en) | 1987-05-05 | 1987-05-05 | Substance with antiviral activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873715281 DE3715281A1 (en) | 1987-05-05 | 1987-05-05 | Substance with antiviral activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3715281A1 true DE3715281A1 (en) | 1988-11-24 |
Family
ID=6327053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19873715281 Withdrawn DE3715281A1 (en) | 1987-05-05 | 1987-05-05 | Substance with antiviral activity |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3715281A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018591A1 (en) * | 1990-05-25 | 1991-12-12 | Mary Katharine Levinge Collins | Inhibition of viral infection |
| EP0610444A4 (en) * | 1991-10-31 | 1995-05-17 | Howard L Elford | Method of treating viral diseases. |
-
1987
- 1987-05-05 DE DE19873715281 patent/DE3715281A1/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018591A1 (en) * | 1990-05-25 | 1991-12-12 | Mary Katharine Levinge Collins | Inhibition of viral infection |
| AU645812B2 (en) * | 1990-05-25 | 1994-01-27 | Mary Katharine Levinge Collins | Inhibition of viral infection |
| EP0610444A4 (en) * | 1991-10-31 | 1995-05-17 | Howard L Elford | Method of treating viral diseases. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69621918T2 (en) | DRUGS FOR TREATING AUTOIMMUNE DISEASES WITH INTERFERON TAU | |
| DE59207523C5 (en) | Prepn. of compsn. contg. human protein and pharmaceuticals for infusion - contains preservatives which are opt. removed before storage, for germ free prod. giving minimal pain upon application | |
| DE102007043186A1 (en) | Cyclohexenone compounds from Antrodia camphorata for the treatment of autoimmune diseases | |
| DE2603321A1 (en) | EMULSION BASED ON A METABOLIZABLE VEGETABLE OIL AND WATER | |
| CH642085A5 (en) | METHOD FOR OBTAINING THE POLAR FRACTION WITH ANTIPSORIATIC EFFECTIVENESS OF AN EXTRACT FROM FERNPLANTS, AND A PREPARATION PRODUCED ACCORDING TO THIS METHOD. | |
| DE3852111T2 (en) | Galenic forms of allergens for sublingual administration. | |
| DE19547317A1 (en) | Antiviral drug | |
| DE3715281A1 (en) | Substance with antiviral activity | |
| DE10030139A1 (en) | Use of phyllanthus components for the treatment or prophylaxis of Flaviviridae infections | |
| DE3873232T2 (en) | A MEDICINAL PRODUCT CONTAINING DIDEOXYNUCLEOSIDE. | |
| DE69112573T2 (en) | IMMUNTIMULATING MEDICINAL PRODUCT CONTAINING POLYGLYCOPEPTIDOLIPID FROM MYCOBAKTERIUM-CHELONAE. | |
| EP1684775B1 (en) | Use of extracts from the pelargonium species | |
| DE1902865A1 (en) | Substituted insulin derivatives, processes for their production and their use in pharmaceutical preparations | |
| DE2034118A1 (en) | Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins | |
| KR20010077131A (en) | Cognitive Enhancer Comprising Ginseng Extract | |
| DE10007771A1 (en) | Immunomodulatory compositions, processes for their preparation and their use | |
| RU92011539A (en) | METHOD OF OBTAINING A BIOLOGICALLY ACTIVE PREPARATION CONTAINING BRAIN PEPTIDES | |
| DE102015115876A1 (en) | Substance for the prophylaxis and treatment of infections caused by influenza viruses | |
| DE69232962T2 (en) | INFLUENZAIVPFSTOFF, INCLUDING SINERGISTIC ADDITIVE INFLUENZAVIRUSINNENKÖRPER CONTAINS | |
| DE4329857A1 (en) | Connection to strengthen the immune system and immune responses | |
| DE1418658A1 (en) | Therapeutic preparations | |
| Matthaeus | Isolierung eines in monomerer und dimerer Form vorliegenden präzipitierenden Antigens aus schweinepestinfiziertem Pankreas und der Nachweis enzymatischer Aktivität in den Immunpräzipitaten | |
| Arnold | Penicillin and early syphilis | |
| DE69530779T2 (en) | MURAMYL PEPTIDE COMPOSITIONS FOR INHIBITING HIV REPLICATION | |
| DE69431320T2 (en) | Use of human interferon-d for the manufacture of a medicament for the treatment of respiratory diseases in cats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |